JP6170435B2 - 改変ノッチンペプチドを含む融合タンパク質及びその使用 - Google Patents

改変ノッチンペプチドを含む融合タンパク質及びその使用 Download PDF

Info

Publication number
JP6170435B2
JP6170435B2 JP2013537908A JP2013537908A JP6170435B2 JP 6170435 B2 JP6170435 B2 JP 6170435B2 JP 2013537908 A JP2013537908 A JP 2013537908A JP 2013537908 A JP2013537908 A JP 2013537908A JP 6170435 B2 JP6170435 B2 JP 6170435B2
Authority
JP
Japan
Prior art keywords
binding
receptor
axl
integrin
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504270A5 (enExample
JP2014504270A (ja
Inventor
アール コクラン ジェニファー
アール コクラン ジェニファー
エス ジョーンズ ダグラス
エス ジョーンズ ダグラス
エス カリオリス ミハリス
エス カリオリス ミハリス
ピンーチュアン ツァイ
ピンーチュアン ツァイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2014504270A publication Critical patent/JP2014504270A/ja
Publication of JP2014504270A5 publication Critical patent/JP2014504270A5/ja
Application granted granted Critical
Publication of JP6170435B2 publication Critical patent/JP6170435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013537908A 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用 Expired - Fee Related JP6170435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41135010P 2010-11-08 2010-11-08
US61/411,350 2010-11-08
PCT/US2011/059599 WO2012064658A1 (en) 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017079525A Division JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2014504270A JP2014504270A (ja) 2014-02-20
JP2014504270A5 JP2014504270A5 (enExample) 2014-12-25
JP6170435B2 true JP6170435B2 (ja) 2017-07-26

Family

ID=46051256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537908A Expired - Fee Related JP6170435B2 (ja) 2010-11-08 2011-11-07 改変ノッチンペプチドを含む融合タンパク質及びその使用
JP2017079525A Expired - Fee Related JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017079525A Expired - Fee Related JP6535361B2 (ja) 2010-11-08 2017-04-13 改変ノッチンペプチドを含む融合タンパク質及びその使用

Country Status (7)

Country Link
US (3) US10844106B2 (enExample)
EP (2) EP3604549A1 (enExample)
JP (2) JP6170435B2 (enExample)
AU (3) AU2011326164B2 (enExample)
CA (1) CA2817197C (enExample)
DK (1) DK2638173T3 (enExample)
WO (1) WO2012064658A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
CA2817197C (en) * 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US9587001B2 (en) 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
SG11201504600UA (en) * 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
US9822347B2 (en) 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
EP3313427A4 (en) * 2015-06-26 2018-12-26 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
CA2994865A1 (en) 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017118761A1 (en) * 2016-01-08 2017-07-13 Iontas Ltd Binding members with altered diversity scaffold domains
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2018044234A1 (en) * 2016-08-31 2018-03-08 Nanyang Technological University Cysteine-rich polypeptides and conjugates and methods of using the same
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
EP3568150A4 (en) 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
CA3049262A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
CN110475565A (zh) 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
WO2018232122A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
AU2018307752A1 (en) 2017-07-24 2020-03-12 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
JP2022513178A (ja) 2018-10-09 2022-02-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 受容体アンタゴニストとしての操作された線維芽細胞増殖因子多様体
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
CN113661240B (zh) * 2019-04-02 2024-11-05 伊莱利利公司 选择和检测结合肽的方法
KR20220002271A (ko) * 2019-04-29 2022-01-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 간세포 성장인자의 조작된 이량체 단편을 이용한 안구 치료 방법
AU2020277470A1 (en) * 2019-05-22 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Drug conjugates and methods of using same
CA3156165A1 (en) * 2019-09-30 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
US20230211001A1 (en) * 2020-07-30 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods
MX2020012914A (es) * 2020-11-27 2022-05-30 Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese Proteina andamio para la generacion de proteinas quimericas de union a antigeno.
WO2025255080A1 (en) * 2024-06-04 2025-12-11 The Children's Hospital Of Philadelphia Hypoxia inducible high-fidelity circuit

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6303749B1 (en) * 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20040132634A1 (en) 2001-01-31 2004-07-08 Frank Sicheri Compositions and methods for regulating the kinase domain of receptor tyrosine kinases
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US7674881B2 (en) 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US10457719B2 (en) * 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
US8394924B2 (en) 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
US8329826B2 (en) 2008-11-06 2012-12-11 The Board Of Trustees Of The Leland Stanford Junior University Surface modification of interpenetrating polymer networks
US8778888B2 (en) 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CA3056999A1 (en) 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
CA2817197C (en) * 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein

Also Published As

Publication number Publication date
WO2012064658A1 (en) 2012-05-18
AU2018200587B2 (en) 2019-12-12
AU2011326164A1 (en) 2013-05-30
EP2638173B1 (en) 2019-06-19
JP6535361B2 (ja) 2019-06-26
US20230227523A1 (en) 2023-07-20
US11498952B2 (en) 2022-11-15
EP2638173A1 (en) 2013-09-18
CA2817197A1 (en) 2012-05-18
US10844106B2 (en) 2020-11-24
AU2018200587A1 (en) 2018-02-15
AU2016210712B2 (en) 2017-10-26
US12240882B2 (en) 2025-03-04
US20140073518A1 (en) 2014-03-13
US20210206824A1 (en) 2021-07-08
JP2014504270A (ja) 2014-02-20
CA2817197C (en) 2020-08-04
JP2017160222A (ja) 2017-09-14
AU2016210712A1 (en) 2016-09-08
EP3604549A1 (en) 2020-02-05
DK2638173T3 (da) 2019-09-30
EP2638173A4 (en) 2014-03-26
AU2011326164B2 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
US12240882B2 (en) Fusion proteins comprising an engineered knottin peptide and uses thereof
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP6041799B2 (ja) Ｔｒａｉｌｒ２特異的多量体足場
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
KR101151805B1 (ko) 바이포달 펩타이드 바인더
TR201906295T4 (tr) IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
US20080160574A1 (en) Chimeric coiled coil molecules
US20100093624A1 (en) Peptide therapeutics that bind vegf and methods of use thereof
TW201107471A (en) Polypeptides selective for αvβ3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
JP6717725B2 (ja) 遺伝子操作した成長因子変異体
US12415868B1 (en) Anti-NME antibody and method of treating cancer or cancer metastasis
KR102717638B1 (ko) 뉴레귤린-4 화합물 및 사용 방법
KR102150419B1 (ko) Pd-l1에 결합하는 펩타이드 및 이의 용도
AU2011347327A1 (en) uPAR-antagonists and uses thereof
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
KR101263424B1 (ko) 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
JP2026514918A (ja) Ｋｒａｓ突然変異を識別する高親和性ｔ細胞受容体及びその応用
WO2018109771A1 (en) Fusion proteins for treatment of cancer
Baber Characterising the molecular interaction between CLEC14A and Multimerin 2
HK40101426A (en) Anti-nme antibody and method of treating cancer or cancer metastasis
CN115991780A (zh) 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用
HK40064429B (en) Anti-nme antibody and method of treating cancer or cancer metastasis
HK1087418B (en) Fusion polypeptides, and use thereof in antivascular tumor therapy
HK1087418A1 (en) Fusion polypeptides, and use thereof in antivascular tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170413

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170630

R150 Certificate of patent or registration of utility model

Ref document number: 6170435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees